Clinical Trial Update: Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating imatinib (Gleevec) in combination with docetaxel (Taxotere) for recurrent non-small cell lung cancer has completed. The trial was spons…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gleevec (Imatinib)
• Taxotere (docetaxel)

Snippet

Sponsor: University of Kansas | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED